Apg-2575
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the Leukemia, Lymphoblastic, Acute, Philadelphia-Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Novartis Pharmaceuticals | Phase 3 | BB |
Blinatumomab Novartis Pharmaceuticals | Phase 3 | BB |
DEXAMETHASONE Novartis Pharmaceuticals | Phase 3 | BB |
Dasatinib SWOG Cancer Research Network | Phase 3 | BB |
Olverembatinib Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BB |
View all 13 →
Same molecule, other indications
Apg-2575 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →